These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32743601)

  • 1. Population Data-Driven Formulation of a COVID-19 Therapeutic.
    Campbell HR; Cecil R; Lodder RA
    medRxiv; 2020 Jul; ():. PubMed ID: 32743601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposed therapeutic agents targeting the Ebola virus: a protocol for a systematic review.
    Sweiti H; Ekwunife O; Jaschinski T; Lhachimi SK
    Syst Rev; 2015 Nov; 4():171. PubMed ID: 26607658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review.
    Sweiti H; Ekwunife O; Jaschinski T; Lhachimi SK
    Curr Ther Res Clin Exp; 2017; 84():10-21. PubMed ID: 28761574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data.
    Thomas L; Birangal SR; Ray R; Sekhar Miraj S; Munisamy M; Varma M; S V CS; Banerjee M; Shenoy GG; Rao M
    Ther Adv Drug Saf; 2021; 12():20420986211041277. PubMed ID: 34471515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents.
    Xu S; Esmaeili S; Cardozo-Ojeda EF; Goyal A; White JM; Polyak SJ; Schiffer JT
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0101523. PubMed ID: 38470112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling and tracking Covid-19 cases using Big Data analytics on HPCC system platformm.
    Villanustre F; Chala A; Dev R; Xu L; LexisNexis JS; Furht B; Khoshgoftaar T
    J Big Data; 2021; 8(1):33. PubMed ID: 33614394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient regimens to reduce COVID-19 hospitalisations: a systematic review and meta-analysis of randomized controlled trials.
    Sullivan DJ; Focosi D; Hanley DF; Cruciani M; Franchini M; Ou J; Casadevall A; Paneth N
    medRxiv; 2023 Jun; ():. PubMed ID: 35665014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds.
    Tzou PL; Tao K; Nouhin J; Rhee SY; Hu BD; Pai S; Parkin N; Shafer RW
    Viruses; 2020 Sep; 12(9):. PubMed ID: 32916958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of preclinical dog studies and absorption modeling to facilitate late stage formulation bridging for a BCS II drug candidate.
    Kesisoglou F
    AAPS PharmSciTech; 2014 Feb; 15(1):20-28. PubMed ID: 24022346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The journey of remdesivir: from Ebola to COVID-19.
    Pardo J; Shukla AM; Chamarthi G; Gupte A
    Drugs Context; 2020; 9():. PubMed ID: 32547625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
    Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
    mBio; 2020 May; 11(3):. PubMed ID: 32444382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracing down the updates on Ebola virus surges: An update on anti-ebola therapeutic strategies.
    Malik S; Waheed Y
    J Transl Int Med; 2023 Sep; 11(3):216-225. PubMed ID: 37662888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses.
    White JM; Schiffer JT; Bender Ignacio RA; Xu S; Kainov D; Ianevski A; Aittokallio T; Frieman M; Olinger GG; Polyak SJ
    mBio; 2021 Dec; 12(6):e0334721. PubMed ID: 34933447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness.
    Mechineni A; Kassab H; Manickam R
    Expert Opin Drug Saf; 2021 Nov; 20(11):1299-1307. PubMed ID: 34338121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines.
    Singh RS; Singh A; Masih GD; Batra G; Sharma AR; Joshi R; Prakash A; Suroy B; Sarma P; Prajapat M; Kaur H; Bhattacharyya A; Upadhyay S; Medhi B
    Heliyon; 2023 Jun; 9(6):e16813. PubMed ID: 37303517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Evidence Informing Treatment Guidelines on Repurposed Drugs for Hospitalized Patients During the Early COVID-19 Pandemic: Corticosteroids, Anticoagulants, (Hydroxy)chloroquine.
    Wüstner S; Hogger S; Gartner-Freyer D; Lebioda A; Schley K; Leverkus F
    Front Public Health; 2022; 10():804404. PubMed ID: 35252090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ebola virus: A gap in drug design and discovery - experimental and computational perspective.
    Balmith M; Faya M; Soliman ME
    Chem Biol Drug Des; 2017 Mar; 89(3):297-308. PubMed ID: 27637475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients' drug regimens: A drug safety simulation study.
    Smith MK; Bikmetov R; Al Rihani SB; Deodhar M; Hafermann M; Dow P; Turgeon J; Michaud V
    Clin Transl Sci; 2021 Sep; 14(5):1799-1809. PubMed ID: 33786990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The National Health and Nutrition Examination Survey (NHANES), 2021-2022: Adapting Data Collection in a COVID-19 Environment.
    Paulose-Ram R; Graber JE; Woodwell D; Ahluwalia N
    Am J Public Health; 2021 Dec; 111(12):2149-2156. PubMed ID: 34878854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors.
    Broni E; Ashley C; Adams J; Manu H; Aikins E; Okom M; Miller WA; Wilson MD; Kwofie SK
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.